FiE 2024: Cabio Biotech launches China-approved NeoHMO for infant formulas
29 Nov 2024 | Cabio Biotech
Jake Liu, head of the Human Nutrition Business Unit at Cabio Biotech in Wuhan, China, announced the approval of new biotech-based NeoHMOs (human milk oligosaccharides) for use in infant formulas. While already featured in adult foods and supplements in Europe and the US, Liu anticipates broader approval in China soon. Cabio also plans to expand its portfolio with additional HMO varieties.
More videos